DNAPrint Quick Ratio from 2010 to 2026

DNAG Stock  USD 0.00001  0.00  0.00%   
DNAPrint Genomics' Quick Ratio is decreasing over the last several years with very volatile swings. Quick Ratio is predicted to flatten to 0.33. Quick Ratio is a measure of a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as (current assets - inventories) divided by current liabilities. View All Fundamentals
 
Quick Ratio  
First Reported
2010-12-31
Previous Quarter
0.57
Current Value
0.33
Quarterly Volatility
0.09903796
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check DNAPrint Genomics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among DNAPrint Genomics' main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 2.8 M or Total Revenue of 2.9 M, as well as many indicators such as Price To Sales Ratio of 1.49, Dividend Yield of 0.0 or Days Sales Outstanding of 12.22. DNAPrint financial statements analysis is a perfect complement when working with DNAPrint Genomics Valuation or Volatility modules.
  
Build AI portfolio with DNAPrint Stock
Check out the analysis of DNAPrint Genomics Correlation against competitors.
For more detail on how to invest in DNAPrint Stock please use our How to Invest in DNAPrint Genomics guide.
The Quick Ratio trend for DNAPrint Genomics offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether DNAPrint Genomics is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.

Latest DNAPrint Genomics' Quick Ratio Growth Pattern

Below is the plot of the Quick Ratio of DNAPrint Genomics over the last few years. It is a measure of a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as (current assets - inventories) divided by current liabilities. DNAPrint Genomics' Quick Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in DNAPrint Genomics' overall financial position and show how it may be relating to other accounts over time.
Quick Ratio10 Years Trend
Very volatile
   Quick Ratio   
       Timeline  

DNAPrint Quick Ratio Regression Statistics

Arithmetic Mean0.59
Geometric Mean0.58
Coefficient Of Variation16.73
Mean Deviation0.06
Median0.63
Standard Deviation0.1
Sample Variance0.01
Range0.3006
R-Value(0.06)
Mean Square Error0.01
R-Squared0
Significance0.83
Slope(0)
Total Sum of Squares0.16

DNAPrint Quick Ratio History

2025 0.57
2011 0.63
2010 0.33

About DNAPrint Genomics Financial Statements

DNAPrint Genomics stakeholders use historical fundamental indicators, such as DNAPrint Genomics' Quick Ratio, to determine how well the company is positioned to perform in the future. Although DNAPrint Genomics investors may analyze each financial statement separately, they are all interrelated. For example, changes in DNAPrint Genomics' assets and liabilities are reflected in the revenues and expenses on DNAPrint Genomics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in DNAPrint Genomics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Quick Ratio 0.57  0.33 

Currently Active Assets on Macroaxis

When determining whether DNAPrint Genomics is a strong investment it is important to analyze DNAPrint Genomics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact DNAPrint Genomics' future performance. For an informed investment choice regarding DNAPrint Stock, refer to the following important reports:
Check out the analysis of DNAPrint Genomics Correlation against competitors.
For more detail on how to invest in DNAPrint Stock please use our How to Invest in DNAPrint Genomics guide.
You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Can Biotechnology industry sustain growth momentum? Does DNAPrint have expansion opportunities? Factors like these will boost the valuation of DNAPrint Genomics. Projected growth potential of DNAPrint fundamentally drives upward valuation adjustments. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating DNAPrint Genomics demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Revenue Per Share
0.004
Quarterly Revenue Growth
(0.65)
Return On Assets
(1.05)
The market value of DNAPrint Genomics is measured differently than its book value, which is the value of DNAPrint that is recorded on the company's balance sheet. Investors also form their own opinion of DNAPrint Genomics' value that differs from its market value or its book value, called intrinsic value, which is DNAPrint Genomics' true underlying value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Because DNAPrint Genomics' market value can be influenced by many factors that don't directly affect DNAPrint Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between DNAPrint Genomics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding DNAPrint Genomics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, DNAPrint Genomics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.